Filed with the SEC on · accession 0001171843-26-005653
EDSA filed a 424B5 (prospectus (offering)) with the SEC on Aug 19, 2026. Edesa Biotech, Inc. is offering common shares, pre-funded warrants, and common share warrants in a public offering. The stock moved +0.7% by the first close after the filing.
Edesa Biotech, Inc. is offering common shares, pre-funded warrants, and common share warrants in a public offering. The offering is being managed by Guggenheim Securities.
Close before
$5.71
Aug 18, 2026
First close after
+0.70%
$5.75
5 trading days
-22.07%
$4.45
Since filing
-62.52%
$2.14
✦ Ask GOAX AI about this filing — what it means for EDSA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for EDSA?
Click hereEDSA filed a 424B5 (Secondary offering). Edesa Biotech, Inc. is offering common shares, pre-funded warrants, and common share warrants in a public offering. The offering is being managed by Guggenheim Securities.
New shares dilute existing holders and are often sold at a discount to the market price.
The final terms of an offering of shares or bonds. Look at price, number of shares and the discount to the market price. Large offerings dilute existing shareholders.
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 424B5 (prospectus (offering)): The final terms of an offering of shares or bonds.
EDSA closed at $5.71 before the filing and $5.75 on Aug 19, 2026 (+0.70%). Five trading days later: $4.45 (-22.07%).
Get alerts when EDSA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days